A consideration of convalescent plasma and plasma derivatives in the care of Severely-ill patients with COVID-19. (October 2020)

• Record Type: Journal Article
• Authors: Lung, Thomas; Kazatchkine, Michel D.; Risch, Lorenz; Risch, Martin; Nydegger, Urs E.
• Is Part Of: Transfusion and apheresis science. Volume 59:Number 5(2020)
• Publication Date: 2020-10
• Subjects: IVIG -- Convalescent plasma -- Plasma exchange -- COVID-19; Blood -- Transfusion -- Periodicals; Hemapheresis -- Periodicals; 615.39
• DOI: 10.1016/j.transci.2020.102936
• Languages: English
• ISSNs: 1473-0502

Abstract

Abstract: The pathogenesis and immunopathological damage of severe forms of COVID-19 resemble acute autoimmune disease sparked by SARS-CoV-2, including an early systemic overproduction of proinflammatory cytokines. Such immunopathological features provide a rationale for the use of passive immunotherapy with convalescent plasma as a source of neutralizing anti-viral antibodies and of anti-inflammatory plasma components. While convalescent plasma therapy is now being evaluated in prospective clinical trials, we further consider the therapeutic potential of human hyper immune globulins, and of heterologous, engineered and monoclonal neutralizing antibodies as anti-viral agents to treat COVID-19. Good medical practice procedures are still needed and is why we also discuss the potential use of polyclonal polyspecific immunoglobulins (IVIG), a therapeutic plasma derivative, with potent anti-inflammatory activity, in severe forms of Covid-19.